Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Recurrent Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate both the efficacy and safety of sintilimab
combined with bevacizumab and radiotherapy in advanced recurrent hepatocellular carcinoma.